$3.190
-0.179 (-5.62%)收盘时
GALT 同业对比
In the context of the broader market, GALT competes directly with industry leaders such as EDIT and ZURA. With a market capitalization of $321.71M, it holds a significant position in the sector. When comparing efficiency, GALT's gross margin of N/A stands against EDIT's 100.00% and ZURA's N/A. Such benchmarking helps identify whether Galectin Therapeutics Inc is trading at a premium or discount relative to its financial performance.
Galectin Therapeutics Inc 财务表现
Galectin Therapeutics has reported consistent losses, with a net income loss of $9.11 million in Q2 2026, a 21% increase from the previous year. The company's EPS for Q2 2026 is -0.14, reflecting ongoing financial struggles.
Financials
FY2026Q2
0.00
Total Revenue
FY2026Q2
YoY:
-13.90%
-3.98M
Operating Profit
FY2026Q2
YoY:
+21.17%
-9.11M
Net Income after Tax
FY2026Q2
YoY:
+16.67%
-0.14
EPS - Diluted
FY2026Q2
YoY:
-63.06%
-2.44M
Free Cash Flow
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。